Stay updated on VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page.

Latest updates to the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2, a minor backend/UI update that does not modify study details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check18 days agoChange DetectedA new revision label 'Revision: v3.4.1' was added and the previous label 'Revision: v3.4.0' was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedShow glossary toggle added; capitalization standardized for 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'. Revision updated to v3.4.0 (from v3.3.4).SummaryDifference0.1%

- Check39 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3.SummaryDifference0.0%

- Check67 days agoChange DetectedThe Locations section now lists many new study sites across the United States, Australia, Canada, Hong Kong, India, Japan, and other regions, broadening the geographic footprint of the trial.SummaryDifference2%

- Check89 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.3.1 was removed from the page.SummaryDifference0.0%

Stay in the know with updates to VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VIS649 Safety and Efficacy in IgA Nephropathy Clinical Trial page.